|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Antithrombotics in intervention cardiology: optimixing treatment and strategies 显示文摘 | Ischinger TA | 1998 | Am J Cardiol1998，82，5： | 1 |
| 2 | Carotid artery stenting in clinical practice results from the Carotid Artery Stenting (CAS)-registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK)显示文摘 | Zahn R Roth E Ischinger T | 2005 | Z Kardiol2005，94，： | 1 |
| 3 | Carotid artery stenting in octogenarians:results from the ALKK Carotid Artery Stent(CAS) Registry 显示文摘 | Zahn R Ischinger T Hochadel M | 2007 | European Heart Journal2007，28，3： | 1 |
| 4 | ImProved outcome with novel device for low-Pressure PTCA in de novo and in-stent lesions显示文摘 | Ischinger TA Solar RJ Hitzke E | | 0，，： | 1 |
| 5 | Experience with a technique for coronary angioplasty of bifureational lesions 显示文摘 | Zack PM Ischinger T | 1984 | Cathet Cardiovasc Diagn1984，10，5： | 1 |
| 6 | Aortic valve calcium score as a predictor for outcome after TAVI using the Corevalve revaling system 显示文摘 | LEBER A W KASEL M ISCHINGER T | 2013 | Int J Cardiol2013，166，3： | 1 |
| 7 | Improved outcome with novel device for low-pressure PTCA in de novo and in-stent lesions显示文摘 | Ischinger T A Solar R J Hitzke E | 2003 | Cardiovasc Radiat Med2003，4，1： | 1 |
| 8 | Embolic protection device for carotid artery stenting; is there a difference between filter and distal occlusive device?显示文摘 | Zahn R Ischinger T Mark B | 2005 | J Am Coil Cardiol2005，45，11： | 1 |
| 9 | Embolic protection devices for carotid artery stenting:is there a difference between filter and distal occlusive devices?显示文摘 | Zahn R Ischinger T Mark B | 2005 | J Am Coil Cardiol2005，45，11： | 1 |
| 10 | Immediate and short-term benefit of muhilesion coronary angioplasty: Influence of degree of revascularization 显示文摘 | VANDORMAEL MG CHAITMAN BR ISCHINGER T | 1985 | J Am Coll Cardiol1985，6，11： | 1 |
| 11 | Carotid artery stenting in clinical practice results from the Carotid Artery Stenting (CAS)-registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK)显示文摘 | Zahn R Roth E Ischinger T | 2005 | Z Kardiol2005，94，3： | 1 |
| 12 | Imp roved outcome with novel device for low pressure POBA in de novo and in2stent lesions 显示文摘 | Ischinger TA Solar RJ Hitzke E | 2003 | Cardiovasc Radiat Med2003，4，： | 1 |
| 13 | Improved outcome with novel device for low-pressure PTCA in de novo and in-stent lesions 显示文摘 | Ischinger TA Solar RJ Hitzke E | 2003 | Cardiovasc Radiat Med2003，4，1： | 1 |
| 14 | Carotid artery stenting in octogenarians:results from the ALKK Carotid Artery Stent (CAS) Registry显示文摘 | Ischinger T Hochadel M | 2007 | Eur Heart J2007，28，： | 1 |
| 15 | Effects of salinity on establishment of Populus fremontii ( cottonwood ) and Tamarix ramosissima (saltcedar) in southwestern United States 显示文摘 | Shafroth P B Friedman J M Ischinger L S | 1995 | Great Basin Naturalist1995，55，： | 1 |
| 16 | Immediate and short-term benefits of multilesion angioplasty:influence and degree of revascularization显示文摘 | Chaitman BR Ischinger T | 1985 | J Am Coll Cardiol1985，6，： | 1 |
| 17 | KohlmeierDegos's disease with primary intestinal manifestation 显示文摘 | Fruhwirth J M ischinger H J Werkgartner G | 1997 | Scand J Gastroenterol1997，32，： | 1 |
| 18 | Thrombectomy with the X-SIZ- ERTM catheter system in the coronary circulation: initial results from a multi-center study 显示文摘 | Ischinger T X-SIZER Study Group | 2001 | J Invasive Cardiol2001，13，2： | 1 |
| 19 | 生物可降解多聚体biolimus洗脱支架与不可降解多聚体西罗莫司洗脱支架用于冠状动脉血运乖建(LEADERS):一项随机非劣效性试验显示文摘背景初步研究表明,从生物可降解多聚体中释出biolimus(西罗莫司类似物)的一种新型洗脱支架有望获得良好的临床效果。本研究比较了biolimus洗脱支架(具有生物可降解多聚体)和西罗莫司洗脱支架(具有不可降解多聚体)的安全性和疗效。方法作者在欧洲的10个研究中心进行了一项多中心、评估音设盲的非劣效性研究。1707例年龄≥18岁、患有慢性稳定性冠心病或急性冠状动脉综合征的患者经计算机产生的一组随机分配序列进行集中随机分组,分别接受biolimus,先脱支架(n=857)或西罗莫司洗脱支架(n=850)植入主要终点是在9个月内心脏性死亡、心肌梗死或具有临床指征的靶血管血运重建(TVR)的复合事件、采用意向治疗分析法对结果进行分析、随机抽取427例患者接受血管造影随访,主要结果指标为9个月时史巢内直径狭窄的百分比。本临床试验在ClinicalTrials.gov网站上注册,注册号为NCT00389220。结果对研究中所有随机分组的患者进行了分析。9个月时biolimus洗脱支架组在主要终点指标上并不劣于西罗莫司洗脱支架组[79例(9%)vs89例(11%),RR0.88,95%CI0.64~1.19,非劣效P=0.003,优势P=0.39]。心脏性死亡发生率[14例(1.6%)vs21例(2.5%),优势P=0.22]、心肌梗死发生率[49例(5.7%)vs39例(4.6%),P=0.30]以及具有临床指征的TVR实施率[38例(4.4%)vs547例(5.5%),P=0.29]在两组中相似.Biolimus洗脱支架组有168例(79%)患者的资料可用于血管造影随访,西罗莫司洗脱支架组有167例(78%)Biolimus洗脱支架组在支架内直径狭窄百分比上不劣于西罗莫司洗脱支架组(20.9%vs 23.3%,差值-2.2%.95%CI-6.0%~1.6%,非劣效P=0.001,优势P=0.26)、结论研究结果表明,从生物可降解多聚体中释出biolimus的洗脱支架安全有效,在对慢性稳定性冠心病或急性冠状动脉综合征患者进行治疗时,它可以取代从不可降解多聚体中释出西罗莫司的洗脱支架。 | Stephan Windecker Patrick W Serruys Simon Wandel Pawel Buszman Stanislaw Trznadel Axel Linke Karsten Lenk Thomas Ischinger Volker Klauss Franz Eberli Roberto Corti William Wijns Marie-Claude Morice Carlo di Mario Simon Davies Robert-Jan van Geuns Pedro Eerdmans Gerrit- Anne van Es Bernhard Meier Peter Jüni 刘少伟(译) | 2009 | 世界临床医学2009，3，3： | 0 |
| 20 | 大学与城市和地区的关系显示文摘你可能曾经认为诸如谷歌、雅虎之类的公司会将其研发基地建在挪威首都奥斯陆。其实不然,它们都选择了距北极圈500公里的一所城市——特隆赫姆。这是为什么? | 芭芭拉·伊欣格(Barbara Ischinger) 贾纳·普卡(Jaana Puukka) 孙丹妮(译) | 2009 | 国外社会科学文摘2009，，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员